Aethlon Medical to Merge with North Immunology in $180M Backed Deal
AEMD is trading near its 52-week low of $1.41 (0.7% below the low).
Summary
Aethlon Medical is merging with private biotech North Immunology in an all-stock deal that will see Aethlon shareholders own just 4.75% of the combined company, which will trade as NRTX. The transaction is paired with an oversubscribed $180 million private placement from top-tier healthcare investors including Bain Capital Life Sciences and Janus Henderson. North Immunology's lead asset, NOR-101, is a bispecific antibody for atopic dermatitis with Phase 1a data expected by mid-2027. Aethlon's legacy Hemopurifier business is being spun off via contingent value rights, giving current holders potential upside from any future monetization. The deal is expected to close in Q1 2027, subject to shareholder and regulatory approvals.
At the time of this announcement, AEMD was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $1.41 to $41.35. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: PR Newswire.